hotspot -WSS

hotspot

author：leisure time 2025-09-27 15:49:30 - browse：9561

Obesity conference attendees with a pink and blue Wegovy sign hanging from the ceiling above. -- obesity coverage from STAT — Wegovy, the obesity drug, was inescapable at the ObesityWeek conference in Dallas. Elaine Chen

DALLAS — Here at ObesityWeek, one of the largest conferences on obesity, Novo Nordisk and Eli Lilly are displaying more than a dozen studies that together carry the message: Our blockbuster weight loss treatments will be worth it for society.

But experts point out that much of this company-funded research does not include the cost of the drugs themselves, which sell at more than $10,000 per year in the U.S. and are meant to be taken indefinitely.

The two major pharmaceutical companies have seen interest skyrocket for their GLP-1-based drugs like Ozempic, Wegovy, and Mounjaro, a new generation of medications that can cut substantial amounts of weight. But insurance plans have been slow to grant wide access to obesity treatments, concerned that the vast amount of people eligible to take them, along with their high price, could lead to significant financial strain.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： After affirmative action ruling, medical educators look to 'holistic review'
Next article： Australia’s approach to dialysis celebrates life

entertainment

WSS

CDC advisory panel says seniors 'may' get RSV vaccine

For longer

Radiation, mainstay of cancer treatment, begins a fade

Why more medical students aren't specializing in primary care

Apellis safety probe of eye disease drug centers on injection needle

Fentanyl is making it harder to start addiction treatment

hotspot

hotspot

hotspot

Hepatitis C has a cure — but many Americans still lack access to it

As pharma fights Medicare drug negotiation, hospitals, docs silent

Heart attack and stroke risk calculators need revising

How a symptom of dementia informs our understanding of creativity

Hepatitis C has a cure — but many Americans still lack access to it

Medicare explains how it will choose drugs for negotiation

Alkermes shareholders re

ASCO eve: Let’s set the table for this year's meeting

23andMe had bad news about my health. I wish a person had delivered it

2024 GOP presidential candidates spar over abortion in debate

Wikipedia

Liver decline slowed by off

AstraZeneca bets AAV gene therapy will still deliver the goods

Apellis safety probe of eye disease drug centers on injection needle

2024 GOP presidential candidates spar over abortion in debate

As pharma fights Medicare drug negotiation, hospitals, docs silent

Addressing health care workers' trauma can help fight burnout

leisure time

hotspot

entertainment

focus